| Autor: |
Viazis N; Gastroenterology Department, Evangelismos Hospital, 10676 Athens, Greece., Argyriou K; Department of Gastroenterology, University Hospital of Larisa, 41334 Larissa, Greece., Kotzampassi K; Endoscopy Unit, Department of Surgery, Aristotle University of Thessaloniki, 15341 Athens, Greece., Christodoulou DK; Department of Gastroenterology, University Hospital of Ioannina, 45500 Ioannina, Greece., Apostolopoulos P; Gastroenterology Department, Army Share Fund Hospital (NIMTS), 11521 Athens, Greece., Georgopoulos SD; Gastroenterology Department, Athens Medical, P. Faliro Hospital, 17562 Athens, Greece., Liatsos C; Gastroenterology Department, 401 General Military Hospital of Athens, 11525 Athens, Greece., Giouleme O; Second Propedeutic Department of Internal Medicine, Medical School, Hippokration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece., Koustenis K; Gastroenterology Department, Evangelismos Hospital, 10676 Athens, Greece., Veretanos C; Gastroenterology Department, Evangelismos Hospital, 10676 Athens, Greece., Stogiannou D; Endoscopy Unit, Department of Surgery, Aristotle University of Thessaloniki, 15341 Athens, Greece., Moutzoukis M; Department of Gastroenterology, University Hospital of Ioannina, 45500 Ioannina, Greece., Poutakidis C; Gastroenterology Department, Army Share Fund Hospital (NIMTS), 11521 Athens, Greece., Mylonas II; Gastroenterology Department, 401 General Military Hospital of Athens, 11525 Athens, Greece., Tseti I; Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A., 14564 Athens, Greece., Mantzaris GJ; Gastroenterology Department, Evangelismos Hospital, 10676 Athens, Greece. |
| Abstrakt: |
Aim: To establish whether the addition of probiotics to a globally accepted Helicobacter pylori (H. pylori)-eradication scheme may reduce the rates of side effects and increase the eradication rates. Methods. Prospective, randomized, placebo-controlled trial of patients receiving eradication therapy for H. pylori in the eight participating centers. All patients received a 10-day proton pump inhibitor containing non-bismuth quadruple therapeutic regimen for H. pylori eradication (omeprazole 20 mg, amoxycillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg all twice daily orally) and were randomized to receive either probiotics (group A) or placebo (group B). The probiotic used combined four probiotic strains, i.e., Lactobacillus Acidophilus, Lactiplantibacillus plantarum, Bifidobacterium lactis, and Saccharomyces boulardii. Results. Data were analyzed for 329 patients in group A and 335 patients in group B. Fifty six (17.0%) patients in group A and 170 (50.7%) patients in group B reported the occurrence of an H. pylori treatment-associated new symptom or the aggravation of a pre-existing symptom of any severity (p < 0.00001). H. pylori was successfully eradicated in 303 patients in group A (92.0%) and 291 patients in group B (86.8%), (p = 0.028). Conclusion: Adding probiotics to the 10-day concomitant non-bismuth quadruple H. pylori eradication regimen increases the eradication rate and decreases side effects. |
